Gastrointestinal safety signals of Janus kinase inhibitors: a real-world pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System.
BACKGROUND Janus kinase inhibitors (JAKis) are increasingly used in dermatology, yet their gastrointestinal safety profiles remain incompletely characterized in real-world practice. Although gastrointestinal adverse events (GIAEs) are generally mild, gastrointestinal perforation remains an important safety concern with...